TP53 and adenocarcinoma: In the progressive LGD group, p53 overexpression was detected in 18/24 (75%) and loss of expression in 4/24 (17%) of HGD and adenocarcinoma samples (end-point), and the numbers in progressive Barrett’s metaplasia group were 9/21 (43%) and 9/21 (43%), respectively.